Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has received full approval from The Bahamas' National Longevity and Regenerative Therapy Board, including ethics committee sign-off, to conduct a commercial Phase 1 study of its VesCell™ autologous stem cell therapy as a treatment for angina, vascular dementia, and pain. Simultaneously, the company disclosed an initial closing of C$380,500 under a non-brokered private placement seeking up to $1,000,000, and confirmed a manufacturing update for its ACP-01 product. Investors may be watching these developments as Hemostemix advances its clinical and commercial programmes within The Bahamas' emerging regenerative-medicine sector.

Key Points

  • Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0)
  • Full LARTA Board and ethics approval granted for a commercial Phase 1 study of VesCell™ covering angina, vascular dementia, and pain
  • Initial private placement closing of C$380,500 via 7,610,000 units at C$0.05; total offering target is up to $1,000,000
  • Investors should watch for Exchange acceptance of the placement and progress of ACP-01 cleanroom manufacturing batches

Hemostemix Clears Full LARTA Regulatory and Ethics Hurdles for VesCell™ Phase 1 Study

The LARTA Board of The Bahamas has granted Hemostemix complete approval — including sign-off from the LARTA Ethics Committee — to proceed with a commercial Phase 1 study of VesCell™. The approval covers three indications: angina, vascular dementia, and pain. The company also stated it is preparing to file a second protocol studying VesCell™ as a treatment for longevity, with the proposed study designed to assess cognition, heart function via left ventricular ejection fraction improvement, and inflammatory biomarker reductions. The release notes that other notable organisations, including Ocugen, Inc. (NASDAQ: OCGN), have also received LARTA approval in The Bahamas.

Private Placement Structure and Intended Use of Proceeds

Hemostemix is completing an initial closing of C$380,500 through the issuance of 7,610,000 units priced at C$0.05 each. Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at C$0.12 for 24 months from closing. An accelerated expiry provision applies if the volume-weighted average trading price reaches at least C$0.15 over any 10 consecutive trading days. Proceeds are intended to support ACP-01 manufacturing, clinical-programme preparation, regulatory submissions, physician education, and general working capital. The offering remains subject to final Exchange acceptance, and all securities carry a statutory hold period of four months and one day.

ACP-01 Manufacturing Advances to Cleanroom Phase as CytoImmune Licence Is Dropped

Hemostemix confirmed it will not proceed with the previously announced CytoImmune bioreactor technology licence from February 19, 2025, stating the transaction did not close and that the 20 million common shares contemplated as consideration were never issued. Despite this, the manufacturing relationship with CytoImmune continues in a different capacity: the company disclosed that CytoImmune has completed ACP-01 test batches outside of the cleanroom and will next move test-batch production into the cleanroom, representing a progression in the manufacturing development process.